araag2/HINT huggingface dataset:
Clinical trial NCT00674466 (phase 2, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: 1.5 mg or 2.0 mg cjc-1134-pc, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Major Inclusion Criteria:

          -  BMI: 27 to 45 kg/m2

          -  Stable Type 2 diabetes mellitus for at least 3 months, as defined by the Investigator

          -  Stable life-style, i.e. diet & physical activity, as determined by the Investigator

          -  Stable metformin daily dose ≥1000 mg for at least 3 months

          -  Glycosylated hemoglobin (HbA1c) at screening ≥ 7.1% and ≤ 11%
Clinical trial NCT00210366 (phase 2, status: terminated)
Conditions: lymphoma, b-cell
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: idarubicin
SMILES: [H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O
Reason stopped: 
    due to slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histological or cytological diagnosis of non-Hodgkin's lymphoma

          -  Disease exclusively localised into the CNS at first diagnosis and failure

          -  Progressive or recurrent disease

          -  Previous treatment with HDMTX containing CHT and/or RT

          -  Presence of at least one target lesion, bidimensionally measurable

          -  Age 18 - 75 years

          -  ECOG performance status < 3 (Appendix 1).

          -  No known HIV disease or immunodeficiency

          -  HBsAg-negative and Ab anti-HCV-negative patients.

          -  Adequate bone marrow function (plt > 100000 mm3, Hb > 9 g/dl, ANC > 2.000 mm3)

          -  Adequate renal function (serum creatinine < 2 times UNL)

          -  Adequate hepatic function (SGOT/SGPT < 3 times UNL, bilirubin and alkaline phosphatase
             < 2 times UNL)

          -  Adequate cardiac function (VEF ≥ 50%)

          -  Absence of any psycological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule

          -  Non-pregnant and non-lactating status for female patients. Adequate contraceptive
             measures during study participation for sexually active patients of childbearing
             potential.

          -  No previous or concurrent malignancies at other sites with the exception of surgically
             cured carcinoma in-site of the cervix and basal or squamous cell carcinoma of the skin
             and of other neoplasms without evidence of disease since at least 5 years.

          -  No concurrent treatment with other experimental drugs.

          -  Informed consent signed by the patient before registration
Clinical trial NCT00525213 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: rob 803, placebo
SMILES: CN(C)CCNC(=O)CN1C2=C(C=C(Cl)C=C2)C2=C1N=C1C=C(C)C(C)=CC1=N2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with RA based on the ARA 1987 revised criteria at least 16 weeks prior to
             study enrolment, Day 0

          -  Have an ACR global functional status class of 1 to 3

          -  Have active disease, defined as the presence of 6 swollen joints and 6 tender joints
             in a 44 joint examination

          -  Have a CRP level at screening of ≥ 1.5 mg/dL

          -  Have been taking oral or parenteral methotrexate (15 mg weekly or above), have been
             using methotrexate for at least 16 weeks (up to Day 0 of study), and have been on a
             stable dose for at least 8 weeks, up to Day 0.

        Exclusion Criteria:

          -  Arthritis onset prior to 16 years old

          -  Any of the following infections:

          -  Known or acute infection that may affect CRP levels

          -  Active tuberculosis

          -  Known chronic infection with human immunodeficiency virus (HIV), hepatitis C virus
             (HCV) or hepatitis B virus (HBV) including positive serology

          -  Ongoing systemic inflammatory condition which may interfere with the results of
             clinical or laboratory tests planned in the study (eg, systemic lupus erythematosus or
             any other systemic rheumatic disease other than RA)
Clinical trial NCT00124449 (phase 2, status: completed)
Conditions: arthritis, rheumatoid
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: abatacept, placebo
SMILES: [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of undifferentiated arthritis

          -  Clinical synovitis of two or more joints

          -  At least one but not more than three of the criteria for diagnosis of RA (1987).

          -  No prior disease modifying anti-rheumatic drugs (DMARDs)/biologics.

          -  Duration of disease must be 18 months or less.

          -  Positive for antibodies against cyclic citrullinated peptides.

        Exclusion Criteria:

          -  Women of child bearing potential who are unwilling or unable to use an acceptable
             method to avoid pregnancy.

          -  Active vasculitis of a major organ system.

          -  Severe or recurrent bacterial infection.

          -  History of cancer in the last five years except certain skin cancers.

          -  Herpes zoster that resolved less than 2 months prior to enrollment
Clinical trial NCT00613951 (phase 2, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin degludec/insulin aspart, insulin degludec/insulin aspart, biphasic insulin aspart, metformin
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Informed consent obtained before any trial-related activities. (Trial-related
             activities are any procedure that would not have been performed during normal
             management of the subject.)

          -  Insulin naïve type 2 diabetes subjects (as diagnosed clinically) for at least 3 months
             (no previous insulin treatment or previous short term insulin treatment maximum 14
             days within the last 3 months)

          -  Treatment with one or two oral anti-diabetic drugs (OADs): metformin, sulfonylurea,
             other insulin secretagogue (e.g. repaglinide, nateglinide), alpha-glucosidase
             inhibitors for at least 2 months at a stable maximally tolerated dose or at least half
             maximally allowed dose according to locally approved summary of product
             characteristics (SPC)

          -  HbA1c, 7.0-11.0 % (both inclusive)

          -  Body Mass Index (BMI), 25.0-37.0 kg/m^2 (both inclusive)

        Exclusion Criteria:

          -  Metformin contraindication according to local practice

          -  Thiazolidinedione (TZD) treatment within previous 3 months prior to Visit 1

          -  Any systemic treatment with products, which in the investigator's opinion could
             interfere with glucose or lipid metabolism (e.g. systemic corticosteroids) within 3
             months prior to randomisation

          -  Subject has a clinically significant, active (during the past 12 months) disease of
             the gastrointestinal, pulmonary, neurological, genitourinary, or haematological system
             (except for conditions associated with type 2 diabetes) that, in the opinion of the
             investigator, may confound the results of the trial or pose additional risk in
             administering trial product
Clinical trial NCT00498043 (phase 2, status: completed)
Conditions: lymphoma, b-cell, lymphoma, large-cell, diffuse
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: r-chop14 induction regimen, r-acvbp14 induction regimen
SMILES: CCO, CCO
Eligibility criteria:

        Inclusion Criteria:

          -  Patient with histologically proven CD20+ diffuse large B-cell lymphoma (WHO
             classification).

          -  Age from18 to 59 years, eligible for transplant.

          -  Patient not previously treated.

          -  Baseline FDG-PET Scan (PET0) performed before any treatment with at least one
             hypermetabolic lesion.

          -  Index prognostic factors (IPI) 2 or 3.

          -  With a minimum life expectancy of 3 months.

          -  Negative HIV, HBV and HCV serologies £ 4 weeks (except after vaccination).

          -  Having previously signed a written informed consent.

        Exclusion Criteria:

          -  Any other histological type of lymphoma.

          -  Any history of treated or non-treated indolent lymphoma. However, patients not
             previously diagnosed and having a diffuse large B-cell lymphoma with some small cell
             infiltration in bone marrow or lymph node may be included.

          -  Central nervous system or meningeal involvement by lymphoma.

          -  Contra-indication to any drug contained in the chemotherapy regimens.

          -  Poor renal function (creatinin level >150 mmol/l), poor hepatic function (total
             bilirubin level >30 mmol/l, transaminases >2.5 maximum normal level) unless these
             abnormalities are related to the lymphoma.

          -  Poor bone marrow reserve as defined by neutrophils <1.5 G/l or platelets <100 G/l,
             unless related to bone marrow infiltration.

          -  Any history of cancer during the last 5 years with the exception of non-melanoma skin
             tumors or stage 0 (in situ)cervical carcinoma.

          -  Any serious active disease (according to the investigator's decision).

          -  Treatment with any investigational drug within 30 days before planned first cycle of
             chemotherapy.

          -  Pregnant or lactating women or women of childbearing potential not currently
             practicing an adequate method of contraception

          -  Adult patient under tutelage.

          -  Impossibility to performed a baseline PET scan (PET0) before randomization and
             treatment beginning
Clinical trial NCT01009060 (phase 2, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: gsk239512, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Clinical diagnosis of Schizophrenia

          2. No acute exacerbation of symptoms requiring hospital admission or step up care in the
             previous six months.

          3. Not on any symptomatic treatment for cognition

        Exclusion Criteria:

          1. Poses a significant homicidal or suicidal risk or evidence of previous homicidal or
             suicidal risk.

          2. Co-morbid psychiatric or significant physical illness

          3. Alcohol or drug abuse or dependence.
Clinical trial NCT00592995 (phase 2, status: completed)
Conditions: huntington disease
ICD codes: G10
Drugs: creatine monohydrate, placebo
SMILES: CN(CC(O)=O)C(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        - Expansion positive or 50% at risk for HD and not diagnosed clinically

        Exclusion Criteria:

        - Unstable medical conditions

        Additional inclusion and exclusion criteria apply.
Clinical trial NCT00088218 (phase 2, status: completed)
Conditions: acute myeloid leukemia, myelodysplastic syndrome
ICD codes: C92.A1, C92.A2, C92.61, C92.62, C92.A0, C92.60, D46.9, D46.C, D46.Z
Drugs: clofarabine, ara-c
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Previously untreated AML and high-risk MDS ( > 10% blasts, or International Prognostic
             Scoring System (IPSS) intermediate-2). Prior therapy with hydroxyurea, single agent
             chemotherapy (e.g. decitabine), hematopoietic growth factors, biological or "targeted"
             therapies are allowed.

          -  Age > 60 years.

          -  Eastern Cooperative Oncology Group (ECOG) performance status </= 2.

          -  Sign a written informed consent form.

          -  Adequate liver function (total bilirubin < 2mg/dL,serum glutamic pyruvic transaminase
             (SGPT) or Serum glutamic oxaloacetic transaminase (SGOT) < x 4 upper limit of normal
             (ULN)) and renal function (serum creatinine < 2mg/dL).

        Exclusion Criteria:

          -  Patients with >= New York Heart Association (NYHA) grade 3 heart disease as assessed
             by history and/or physical examination.
Clinical trial NCT00299286 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: lapatinib, lapatinib-placebo
SMILES: CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1
Eligibility criteria:

        Inclusion Criteria:

        Patients must have a histological or cytologic diagnosis of primary breast cancer with a
        tumour size adequate for multiple core biopsies Informed signed consent Scheduled for
        primary surgery Expected to be compliant for duration of study Age<80 ECOG performance
        status 0-2 (Karnofsky >60%) Cardiac ejection fraction within the institutional range of
        normal as measured by echocardiogram or MUGA scan Eligibility of patients receiving
        medications known to affect, or with the potential to affect the activity or
        pharmacokinetics of lapatinib will be determined following review by the Trial Coordinator
        The effects if lapatinib on the developing fetus are unknown. For this reason, women of
        childbearing potential must agree to use adequate non-hormonal contraception for the
        duration of study participation.

        Able to swallow and retain oral medication.

        Exclusion Criteria:

        Patients with prior diagnosis of malignancy except in situ disease or basal cell carcinoma
        of the skin.

        Patients may be receiving any other investigational agents or receiving concurrent
        anticancer therapy. In addition, all herbal (alternative) medicines are excluded.

        Evidence of metastatic disease. Use of hormonal therapy such as oral contraceptives or
        hormonal replacement therapy within 4 weeks of study entry.

        Regular use of steroid hormones or other agents that could influence study endpoints
        History of allergic reactions attributed to compounds of similar chemical or biologic
        composition to GW572016.

        Uncontrolled inter-current illness including, but not limited to, ongoing or active
        infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
        arrhythmia, or psychiatric illness/ social situations that would limit compliance with
        study requirements.
Clinical trial NCT00671073 (phase 2, status: completed)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: oglemilast, placebo, oglemilast, oglemilast
SMILES: CS(=O)(=O)NC1=CC2=C(OC3=C2C(=CC=C3OC(F)F)C(=O)NC2=C(Cl)C=NC=C2Cl)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CS(=O)(=O)NC1=CC2=C(OC3=C2C(=CC=C3OC(F)F)C(=O)NC2=C(Cl)C=NC=C2Cl)C=C1, CS(=O)(=O)NC1=CC2=C(OC3=C2C(=CC=C3OC(F)F)C(=O)NC2=C(Cl)C=NC=C2Cl)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Presence of COPD as defined by GOLD criteria (2006); post-bronchodilator FEV1/FVC
             <70%, and post-bronchodilator FEV1 >30% and < 80% predicted

          -  Current or former cigarette smoker

        Exclusion Criteria:

          -  Long-term oxygen use of > 15 hours a day

          -  Symptoms consistent with a significant asthmatic component (e.g. atopic disease,
             allergic symptoms)

          -  Any COPD exacerbations within 30 days prior to study entry or during run-in

          -  History of chronic or recurrent gastrointestinal disorder associated with bleeding in
             previous 12 months

          -  Presence of clinical significant pulmonary disease other than COPD
Clinical trial NCT01457846 (phase 2, status: terminated)
Conditions: gastro-oesophageal junction cancer, gastric cancer
ICD codes: C19, D12.7, Z85.048, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: azd4547, paclitaxel
SMILES: COC1=CC(OC)=CC(CCC2=CC(NC(=O)C3=CC=C(C=C3)N3C[C@H](C)N[C@H](C)C3)=NN2)=C1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Female or male aged 25 or over

          -  Histological diagnosis of locally advanced or metastatic gastro adenocarcinoma
             (including adenocarcinoma of the lower third of the oesophagus or the gastro
             oesophageal junction )

          -  Radiographically confirmed progression after 1 prior chemotherapy or chemoradiotherapy
             for gastric cancer. Suitable for and expected to benefit from paclitaxel monotherapy.

          -  At least one lesion, not previously irradiated, that has baseline at least 10mm in the
             longest diameter for non nodal lesions and is assessed by Computerised Tomography (CT)
             or Magnetic Resonance Imaging (MRI)

          -  Provision of either an archival tumour sample or a fresh tumour sample for
             confirmation of FGFR2 polysomy/gene amplification

        Exclusion Criteria:

          -  Prior exposure to AZD4547 or history of hypersensitivity other drugs similar in
             structure or class to AZD4547. Hypersensitivity to paclitaxel or formulated in
             cremophor EL (polyoxyethylated castor oil)

          -  Prior taxane treatment for gastric cancer with the exception of adjuvant/neo-adjuvant
             therapy given > 6 months; Major surgery, radiotherapy with wide field of radiation or
             any cancer treatment within 4 weeks before the first dose of the study treatment

          -  With the exception of alopecia, any unresolved toxicities from prior therapy with a
             Common Terminology Criteria for AE (CTCAE) grade >1 at the time of starting study
             treatment.

          -  Blood and Echocardiogram (ECG) readings that are deemed to be abnormal by falling
             outside of the reference ranges in the protocol inclusion/exclusion section.

          -  Taking other regular medication that are predicted to interact with AZD4547 due to
             their route of metabolism.
Clinical trial NCT00622193 (phase 2, status: completed)
Conditions: carcinoma, non-small-cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: anamorelin hcl, anamorelin hcl, placebo
SMILES: CN(C)N(C)C(=O)[C@@]1(CC2=CC=CC=C2)CCCN(C1)C(=O)[C@@H](CC1=CNC2=CC=CC=C12)NC(=O)C(C)(C)N, CN(C)N(C)C(=O)[C@@]1(CC2=CC=CC=C2)CCCN(C1)C(=O)[C@@H](CC1=CNC2=CC=CC=C12)NC(=O)C(C)(C)N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  stage IIIB or IV NSCLC

          -  eligible for treatment of NSCLC with paclitaxel and carboplatin +/- bevacizumab

        Exclusion Criteria:

          -  mixed large and small cell histologies for lung cancer

          -  significant obesity, BMI > 30
Clinical trial NCT00593879 (phase 2, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: mecamylamine
SMILES: CNC1(C)C2CCC(C2)C1(C)C
Eligibility criteria:

        Inclusion Criteria:

        (A) Open Phase

          -  Male or female subjects aged 18-70 years.

          -  Diagnosis of major depressive disorder (MDD) according to DSM-IV and confirmed via
             MINI diagnostic scale.

          -  Able to give written informed consent.

          -  HAMD-17 score greater than 21.

          -  CGI-Severity of Illness score greater than or equal to 4.

          -  No clinically significant abnormality on physical examination, vital signs, ECG or
             laboratory tests (biochemical, hematological, urinary) at screening.

          -  Women of child bearing potential with a negative urine pregnancy test and willing to
             use acceptable methods of contraception.

        (B)Double Blind Phase:

          -  Subjects still to meet DSM-IV criteria for MDD.

          -  Subjects continue to meet all of the inclusion and exclusion criteria.

          -  HAMD-17 score greater than or equal to 14.

          -  CGI severity of illness score greater than or equal to 4.

          -  Women of child bearing potential with a negative urine pregnancy test and willing to
             use acceptable methods of contraception.

        Exclusion Criteria:

          -  Aged below 18 years and above 70 years.

          -  Failure to meet DSM IV criteria for MDD.

          -  HAMD-17 less than or equal to 21 (open-label phase only).

          -  CGI Severity of Illness score less than 4.

          -  Clinically significant changes in physical examination, vital signs, ECG or laboratory
             tests at screening.

          -  Any other co morbid psychiatric illness confirmed by MINI diagnostic scale, especially
             bi-polar disorder, schizophrenia or dementia.

          -  Subjects with significant suicidal risk upon clinical assessment.

          -  Subjects who have treatment resistant depression i.e. who have failed adequate course
             (daily dose and duration of treatment) of one or more antidepressants.

          -  History of alcohol or drug abuse over the last 6 months.

          -  History of seizures or seizure disorders.

          -  Seropositive for HIV or hepatitis B (antibody or antigen).

          -  Any other severe progressive and uncontrolled medical condition.

          -  For controlled other medical conditions, medication to be unchanged over the 2 months
             preceding screening, or else the patient will be excluded.

          -  Subjects with Glaucoma, Kidney Disease or Heart Disease.

          -  Known hypersensitivity to mecamylamine.

          -  Women of child bearing potential not taking adequate contraception and women
             breastfeeding.

          -  Other investigational drug in previous 30 days.